The Drugs Controller General of India (DCGI) has been ordered to review the good manufacturing practices (GMP) compliance of the Ranbaxy Laboratories' manufacturing facilities in India after the company faced flak in the US for non-adherence to GMP. Besides, DCGI has also been asked to ascertain the quality, safety and efficacy of drugs manufactured for the domestic market at these facilities.
Ranbaxy USA Inc recently was admitted in the US District Court of Maryland for manufacturing and distribution of certain drugs not in conformity with GMP regulation which is considered as adulterated drugs as per the US law and agreed to pay a fine of $500 million.
Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1834.40 |
| Dr. Reddys Lab | 1306.80 |
| Cipla | 1362.85 |
| Zydus Lifesciences | 940.10 |
| Lupin | 2459.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: